Health Care Costs in Patients with Painful Diabetic Peripheral Neuropathy Prescribed Pregabalin or Duloxetine

Burke, J. P.; Sanchez, Robert J.; Joshi, Ashish V.; Cappelleri, Joseph C.; Kulakodlu, Mahesh; Halpern, Rachel

doi:10.1111/j.1533-2500.2011.00478.x

Cited by 10 publications

(19 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some studies have analyzed health-care costs in patients with PDPN treated with pregabalin, duloxetine, or other usually used drugs. In general, all show similar results, with a good cost-effective profile for both drugs 132–134…”

Section: Pharmacological Therapeutic Modalities For Diabetic Neuropatsupporting

confidence: 53%

Guidelines in the management of diabetic nerve pain clinical utility of pregabalin

Vinik¹,

Casellini²

2013

DMSO

View full text Add to dashboard Cite

Diabetic peripheral neuropathy is a common complication of diabetes. It presents as a variety of syndromes for which there is no universally accepted unique classification. Sensorimotor polyneuropathy is the most common type, affecting about 30% of diabetic patients in hospital care and 25% of those in the community. Pain is the reason for 40% of patient visits in a primary care setting, and about 20% of these have had pain for greater than 6 months. Chronic pain may be nociceptive, which occurs as a result of disease or damage to tissue with no abnormality in the nervous system. In contrast, neuropathic pain is defined as “pain arising as a direct consequence of a lesion or disease affecting the somatosensory system.” Persistent neuropathic pain interferes significantly with quality of life, impairing sleep and recreation; it also significantly impacts emotional well-being, and is associated with depression, anxiety, and noncompliance with treatment. Painful diabetic peripheral neuropathy is a difficult-to-manage clinical problem, and patients with this condition are more apt to seek medical attention than those with other types of diabetic neuropathy. Early recognition of psychological problems is critical to the management of pain, and physicians need to go beyond the management of pain per se if they are to achieve success. This evidence-based review of the assessment of the patient with pain in diabetes addresses the state-of-the-art management of pain, recognizing all the conditions that produce pain in diabetes and the evidence in support of a variety of treatments currently available. A search of the full Medline database for the last 10 years was conducted in August 2012 using the terms painful diabetic peripheral neuropathy, painful diabetic peripheral polyneuropathy, painful diabetic neuropathy and pain in diabetes. In addition, recent reviews addressing this issue were adopted as necessary. In particular, reports from the American Academy of Neurology and the Toronto Consensus Panel on Diabetic Neuropathy were included. Unfortunately, the results of evidence-based studies do not necessarily take into account the presence of comorbidities, the cost of treatment, or the role of third-party payers in decision-making. Thus, this review attempts to give a more balanced view of the management of pain in the diabetic patient with neuropathy and in particular the role of pregabalin.

show abstract

Section: Pharmacological Therapeutic Modalities For Diabetic Neuropatsupporting

confidence: 53%

Guidelines in the management of diabetic nerve pain clinical utility of pregabalin

Vinik¹,

Casellini²

2013

DMSO

View full text Add to dashboard Cite

show abstract

“…Costs due to early retirement were not included in the calculations; however, data from 2012 show that back pain (and other musculoskeletal disorders) is the reason for only approximately 12% of the cases of early retirement nowadays [5]. Even higher costs were reported from the USA, where annual costs resulting from chronic lower back pain patients were estimated at almost $12,000 for medical care alone, with a large proportion coming from in- and outpatient service [6]. The problem of back pain may even increase in future, since members of the western population are showing a decrease in physical activity and an increase in weight over the years (e.g., [7]).…”

Section: Introductionmentioning

confidence: 99%

Back Pain in Poland and Germany: A Survey of Prevalence and Association with Demographic Characters

Henn¹,

Schier

Brian³

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

Background. Back pain is the most common form of pain and leads to high costs in all medical care systems. Objective. The present study examines the prevalence of back pain and its associations with some basic demographics. Methods. Two samples from Poland and Germany (about n = 500 each) were examined via Internet regarding back pain, gender, age, and body mass index (BMI). Results. Back pain is more common in women than in men (risk ratio about 1.7), and a high BMI constitutes an additional risk factor. Age was not related to back pain prevalence. Conclusion. Congruent results in two countries based on the same measure of back pain lead to the assumption that much of the variety found in estimates of back pain are due to inconsistent assessment. For future research, a definition of common criteria on how to assess back pain would be an asset.

show abstract

“…Of the 255 abstracts, based on the inclusion criteria, 56 were selected for further review in full text. In the past 11 years, 55 publications examined economic outcomes associated with pregabalin in FM or neuropathic pain . These 55 publications presented results from 53 studies.…”

Section: Resultsmentioning

confidence: 99%

“…Our review identified 28 primary studies examining per‐patient costs associated with pregabalin for neuropathic pain and FM. Most studies were retrospective analyses reporting direct costs only, and most were conducted in the US, with 2 from Spain and 1 from Sweden . In the US, patients receiving pregabalin for FM had a similar or higher amount of healthcare use following treatment initiation compared with standard therapies .…”

Section: Resultsmentioning

confidence: 99%

A Systematic Review of Pharmacoeconomic Studies for Pregabalin

et al. 2014

View full text Add to dashboard Cite

show abstract

Health Care Costs in Patients with Painful Diabetic Peripheral Neuropathy Prescribed Pregabalin or Duloxetine

Cited by 10 publications

References 24 publications

Guidelines in the management of diabetic nerve pain clinical utility of pregabalin

Guidelines in the management of diabetic nerve pain clinical utility of pregabalin

Back Pain in Poland and Germany: A Survey of Prevalence and Association with Demographic Characters

A Systematic Review of Pharmacoeconomic Studies for Pregabalin

Contact Info

Product

Resources

About